Rexidin M FORTE

Quick links

Choose a section

Quick links to important sections

Advertisements

Rexidin M FORTE

Advertisements

Treatment option:

Advertisements

Overview of Rexidin M FORTE

Property Description
Active Ingredients Chlorhexidine Gluconate, Metronidazole, Lidocaine (Lignocaine)
Form Topical preparation (solution, gel, or paste)
Pharmacological Class Antimicrobial agent & Local anesthetic
Common Use Oral health management and localized relief
Origin Synthetic combination product

What Type of Medicine is Rexidin M FORTE?

Rexidin M FORTE is classified as a potent fixed-dose combination product designed for topical application in the oral cavity. It delivers simultaneous broad-spectrum antimicrobial and local anesthetic activity. This preparation is a high-strength formulation, often available as a gel or paste, positioning it for specialized oral health management where concentrated local action is required. Pharmacological studies have clinically recognized the efficacy of combining these specific agents to achieve a rapid, localized therapeutic effect.

Composition: A Synthetic Triad of Active Ingredients

The medicine contains three synthetic active substances: Chlorhexidine Gluconate, Metronidazole, and Lidocaine (Lignocaine). Chlorhexidine Gluconate is widely used as a broad-spectrum antiseptic. The inclusion of Metronidazole specifically targets anaerobic bacteria and protozoa, agents often implicated in dental issues. Lidocaine provides rapid numbing by acting as an amide-class local anesthetic. This compound temporarily interrupts pain signaling in the applied area, providing localized comfort. These components are typically formulated into a base, such as an aqueous solution or semisolid gel, for topical route of administration on oral and gingival tissues.

What is the General Purpose of Rexidin M FORTE?

The general purpose of this combination is to support oral health management through a multifactorial action delivered directly to the affected site. By pairing key antimicrobial agents with a local anesthetic, the preparation is fundamentally designed to achieve both microbial control and immediate symptomatic relief. Chlorhexidine is used to reduce oral bacterial counts. This means the medicine helps achieve a cleaner oral environment by preventing plaque and microbe build-up.

Regulatory References

  1. Lidocaine
Advertisements

What side effects are possible with Rexidin M FORTE?

Official Side Effects and Regulatory Safety Profile

The safety profile for this topical combination is established by government regulatory bodies based on the documented adverse reactions of its active components (Chlorhexidine Gluconate, Metronidazole, and Lidocaine).

Adverse effects are categorized by the frequency of their occurrence:

  • Very Common (Affecting ge 1 in 10): Altered sense of taste (dysgeusia) and reversible discoloration of the tongue.
  • Common (Affecting ge 1 in 100 to < 1 in 10): Reversible staining of teeth and dental work, dry mouth (xerostomia), nausea, and a localized burning sensation.
  • Uncommon/Rare: Headache, swelling of the salivary glands (parotitis), and various hypersensitivity reactions, including urticaria.

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions, though very rare, are officially documented in regulatory labeling. These include anaphylactic shock and angioedema, which are severe, immediate hypersensitivity events. Additionally, rare cases of methemoglobinemia are associated with excessive systemic absorption of Lidocaine, a critical safety note in official prescribing information.

The regulatory profile highlights two key safety patterns related to exposure. Local irritation and taste disturbances are typically more noticeable at the start of treatment. Conversely, both the degree of reversible staining and the potential risk of bacterial or fungal superinfection are associated with prolonged use of the antimicrobial components. Official safety constraints advise particular caution for pediatric patients due to the potential for increased systemic absorption of Lidocaine, and for patients with hepatic impairment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Documented Manifestations and Severe Outcomes

Overdose, typically resulting from the accidental ingestion of a large amount of the topical preparation, primarily involves the systemic effects of the active components, particularly the local anesthetic (Lidocaine). The official overdose profile indicates initial signs of Central Nervous System (CNS) excitation, which may include dizziness, confusion, blurred vision, tremors, or metallic taste.

If systemic toxicity progresses, regulatory documents classify this as a risk for life-threatening outcomes. These severe outcomes can include the onset of seizures (convulsions), followed by CNS depression leading to respiratory arrest. Cardiovascular effects, such as hypotension (low blood pressure) and cardiac arrest, are also documented risks associated with severe systemic exposure. Gastrointestinal distress, including nausea and vomiting, is noted following ingestion.

Required Emergency Actions and Supportive Management

In the event of suspected overdose or accidental ingestion, official regulatory guidance mandates seeking immediate medical attention. You must contact a Poison Control Center or emergency services (e.g., 911 or 999) without delay.

The management described in prescribing information consists of symptomatic and supportive therapy. Close monitoring of vital signs is required to manage potential CNS and cardiovascular complications. Regulatory documents note that no specific antidote is known for the Metronidazole component, and for severe Lidocaine toxicity, complex procedures are used, but dialysis is considered of negligible value.

Advertisements

Therapeutic Uses of Rexidin M FORTE

What Rexidin M FORTE Treats: Main Uses and Benefits

The therapeutic scope of this specialized oral preparation involves managing symptoms related to physical discomfort and symptoms related to inflammatory or irritative states. The category of ingredients is generally used in areas where short-term symptom management is appropriate, particularly for the relief of oral discomfort. Topical agents like chlorhexidine are commonly applied to help address gum disease.

The medication is commonly used across conditions presenting with localized discomfort, including gingivitis, mouth ulcers, and post-dental procedure recovery. It is relevant in contexts marked by increased discomfort or tension and is used for managing symptoms that interfere with daily functioning. The general patient benefit is that it provides support that helps ease the symptoms that interfere with daily functioning. It is considered relevant for episodes where acute manifestations interfere with function.

Key Symptomatic Domains

Rexidin M FORTE is applied in contexts marked by increased discomfort or tension. It is used in situations involving certain distressing symptoms, such as active gum inflammation, painful oral sores, and localized irritation following minor surgeries. This assists with maintaining functional stability and contributes to improved comfort during periods when symptoms are more noticeable.


Quick Fact: Relief for Physical Discomfort Rexidin M FORTE is commonly used when symptoms intensify, offering supportive relief for symptoms related to physical discomfort associated with oral lesions.

Regulatory References

  1. MedlinePlus, a service of the NIH
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Rules and Contraindications

The eligibility profile for Rexidin M FORTE is defined by regulatory documentation, establishing clear restrictions on who can and cannot use the medicine. Eligibility is primarily restricted based on hypersensitivity, age, and pre-existing health conditions.

Absolute Contraindications

  • Hypersensitivity: Use is strictly prohibited for individuals with a known allergy or hypersensitivity to Chlorhexidine, Metronidazole, Lidocaine, or any other excipients in the formulation.
  • Pediatric Use: The medicine is not recommended for use in children under 12 years of age, often due to a lack of established safety and efficacy data for this specific age group.

Conditional Eligibility (Use with Caution)

Population Group Regulatory Status
Severe Organ Impairment Use with caution in patients with severe hepatic (liver) or renal (kidney) dysfunction.
Cardiovascular Conditions Use with caution in patients with pre-existing heart conditions, such as heart block.
Pregnancy and Lactation Use is conditional; requires caution and should only be used if deemed necessary.
Compromised Oral Mucosa Use with caution in patients with injured or traumatized oral tissue due to the risk of enhanced systemic absorption.

These official rules mandate that the medicine is reserved for the general adult population unless specific health constraints require its use to be strictly limited or prohibited, as defined by the government-approved label.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for this combination product is structured around the systemic interaction potential of the Metronidazole and Lidocaine components. Co-administration with Disulfiram is formally contraindicated due to the reported risk of psychotic reactions related to Metronidazole. A strict timing rule also mandates the avoidance of alcoholic beverages and products containing Propylene Glycol during therapy and for at least three days following the final dose, as this combination may result in a Disulfiram-like reaction.

Regarding drug-drug interactions, Metronidazole is documented to potentiate the anticoagulant effect of Warfarin and other Coumarin anticoagulants, leading to a prolongation of prothrombin time. The Lidocaine component is metabolized by liver enzymes (CYP3A4 and CYP1A2), meaning co-administration with strong CYP inhibitors (e.g., Itraconazole) can result in increased systemic drug exposure (AUC and Cmax). A pharmacodynamic interaction is noted for concurrent use with other local anesthetics, which carries an additive risk of systemic toxicity.

Regulatory labeling includes a population-specific caution that the risk of interaction and drug accumulation is significantly heightened in individuals with severe liver disease due to their reduced capacity for drug clearance.

Advertisements

Mechanism of Action

Rexidin M FORTE mediates anti-inflammatory and antimicrobial action through a dual mechanism. The primary component, Compound A, achieves its anti-inflammatory effects through the non-selective inhibition of cyclooxygenase-1 ( COX-1) and cyclooxygenase-2 ( COX-2) enzymes. This interaction decreases the biosynthesis of pro-inflammatory prostaglandins from arachidonic acid precursors.

The second component, Compound B, is a 5-HT₃ receptor antagonist. It specifically and reversibly binds to the 5-HT₃ receptor, a ligand-gated ion channel, found on peripheral afferent nerves. This binding leads to the closure of the ion channel, preventing the influx of cations and interrupting the signaling cascade that transmits afferent signals. This dual mechanism results in the modulation of the cellular environment.

The combination of Compound A's COX inhibition and Compound B's 5-HT₃ antagonism provides a concurrent anti-inflammatory and signaling-modulation mechanism.

Advertisements

Dosage and Administration Information

How to use Rexidin M FORTE

This section describes the administration protocol for Rexidin M FORTE, regarding its components and fixed-dose combination structure.

Administration Scope

Property Instruction
Route of administration Topical application to the oromucosal surfaces (gums, lesions).
Dosing schedule Application of a thin film or small amount of gel, applied directly onto the affected area.
Timing in relation to meals To ensure effective local contact, eating or drinking must be avoided for at least 30 minutes following application.
Age-group administration rules Use is not recommended for children below 12 years of age and requires caution in adolescents and older adults.
Special procedural conditions The gel must not be swallowed and is for external oral use only.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Topical / Oromucosal
Frequency pattern Once or twice daily (Time-bound regimen)
Use-context constraints Usage is defined for a short-term course, typically limited to a maximum of four weeks.

Resulting Procedural Structure

Step sequence:

  • Application should occur after toothbrushing; the mouth must be thoroughly rinsed with water beforehand to prevent inactivation of the active ingredients by anionic toothpaste agents.
  • Apply a small amount of the gel directly to the affected area.
  • Retain the gel locally without swallowing and adhere strictly to the post-application wait time.

Connection to the overall use protocol (2–4 sentences): A structured local use protocol defines specific parameters for administration and post-application activities. These instructions dictate the preparation steps and the required waiting period necessary for the chemical activity of the fixed-dose combination. The defined duration limits and age rules establish the boundaries of use for this preparation.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rexidin M FORTE

Evidence for Use in Managing Gum Inflammation

Some research exploring the antimicrobial components, Chlorhexidine and Metronidazole, has been conducted using Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies was studied for conditions characterized by fluctuating or episodic manifestations of gum disease, known as gingivitis. Researchers examined various outcomes linked to inflammatory or irritative states, such as monitoring changes in clinical indices that track bleeding, gum inflammation, and the accumulation of dental plaque.

Findings describe patterns observed in the studies related to a measured change in scores for both inflammation and plaque in groups receiving the active antimicrobial components. What remains uncertain is the long-term observation of these patterns, as follow-up durations were limited, typically extending only up to a few months.

Evidence for Use in Managing Painful Oral Sores and Ulcers

Research has explored the use of the antimicrobial components of this combination in the context of conditions associated with acute or disruptive episodes, such as minor oral ulcers. Studies utilized comparative clinical designs. Patient-reported outcomes describing perceived discomfort were a central focus, along with tracking physical changes like wound surface area reduction.

Research focusing on these outcomes related to physical discomfort reported measured differences in discomfort and post-operative pain scores in the observed populations. Research providing direct insight into data show patterns related to the full three-component formula and the recurrence patterns of oral ulcers is limited. Follow-up durations were limited, generally extending only for one or two weeks.

What Is Still Uncertain About the Available Research

Studies help show what has been observed so far, but several limitations exist in the broader evidence landscape. The follow-up durations were limited in most trials, and long-term effects are not fully established. Furthermore, the specific contribution of the third active ingredient, Lidocaine, to the antimicrobial or anti-inflammatory outcomes is not clearly defined in many of the core efficacy studies, as it is primarily tracked for its effect on outcomes related to physical discomfort. Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Rexidin M FORTE (FAQ)


Q: How quickly should I expect to see an effect from Rexidin M FORTE?

A: Regulatory information indicates that the local anesthetic component is designed to work quickly. It temporarily interrupts pain signals at the area where the gel is applied. This mechanism means that the product is intended to provide rapid, localized comfort shortly after use.


Q: How long does the effect of Rexidin M FORTE usually last?

A: Studies related to the antimicrobial component show that it has a property called "substantivity," meaning it binds to the tissues inside the mouth. Because of this binding, official data suggests that effects of the antimicrobial agent can persist on the oral mucosa for up to 12 hours following a single application.


Q: What should I do if my mouth feels dry after using Rexidin M FORTE?

A: According to the official safety profile, dry mouth, also known as xerostomia, is a commonly reported side effect. This reaction is generally localized to the mouth and is often more noticeable when treatment is first started. Official documents describe this side effect as an expected part of the treatment for some individuals.


Q: Why is the drug intended for short-term use in some cases?

A: Official regulatory guidelines define the use of this medicine for a short-term course, typically limited to a maximum of four weeks. This duration limit is based on data indicating that prolonged use is associated with an increased risk of reversible staining of teeth and dental work, as well as the potential for a secondary bacterial or fungal superinfection.


Q: Can Rexidin M FORTE be swallowed accidentally without causing a serious issue?

A: The product is strictly intended for topical, external oral use, and official guidelines state that it should not be swallowed. However, regulatory information also notes that the main antimicrobial component is poorly absorbed from the digestive tract. This means that if a small amount is accidentally swallowed, systemic absorption is generally considered to be minimal.


Q: Is there any risk of developing resistance with long-term use of Rexidin M FORTE?

A: The medicine contains an antibiotic component, Metronidazole. Regulatory principles for all antimicrobial agents emphasize the importance of use for the shortest duration described. This practice is advised to limit the risk of bacteria developing resistance to the drug over time.


Q: Is it possible for Rexidin M FORTE to hide symptoms of a more serious condition?

A: The local anesthetic in the product provides immediate symptomatic relief of pain, which is the intended purpose. However, a caution described in the regulatory profile notes that symptomatic relief could potentially mask the signs of a more serious underlying condition.


Q: What data exists regarding the effects of Rexidin M FORTE on the normal oral microbiome?

A: Research evidence describes the function of the antimicrobial component as targeting and reducing the overall oral bacterial counts and plaque accumulation. This action will inherently affect the microbial environment (the oral microbiome) in the mouth, but official documents focus primarily on the reduction of pathogenic organisms.


Q: Is Rexidin M FORTE an antibiotic or an antiseptic?

A: Rexidin M FORTE contains two key antimicrobial components, which means it has both antiseptic and antibiotic properties. Specifically, official documents classify Metronidazole as an antibiotic and Chlorhexidine as a broad-spectrum antiseptic agent.


Q: What if I forget to use Rexidin M FORTE at the usual time?

A: Official documents governing the administration of this medicine typically include instructions for managing a forgotten application. Generally, the guidance indicates that the forgotten dose may be applied as soon as it is remembered, unless the time is very close to the next scheduled dose.


Q: Is it okay to use Rexidin M FORTE with other mouthwashes?

A: Official instructions related to the administration of the antimicrobial component advise that other mouthwashes should not be used immediately following application. This is because certain agents in other oral products may interfere with the effectiveness of the medicine.


Q: Is Rexidin M FORTE available without a prescription?

A: Due to the combination of the active ingredients, specifically the inclusion of the antibiotic Metronidazole, this product is generally classified as prescription-only in most regulatory regions. Its use is managed under professional oversight due to its potency and specialized use conditions.


Q: Can I use Rexidin M FORTE if I have dentures or other dental work?

A: The gel formulation has been studied for use in managing conditions such as denture stomatitis, suggesting that its use is possible with dental work. Regulatory-linked documents advise that when used alongside dentures, official documents indicate that specific instructions for cleaning may apply to manage potential side effects.


Q: What are the known differences in usage between a mouthwash and a gel formulation of this drug?

A: Official regulatory documents describe a key difference in usage based on the formulation type. The mouthwash preparation is designed to be used as a rinse throughout the oral cavity, while the gel formulation is specifically intended for topical application of a small amount directly to the localized affected area.


Q: What does 'bioavailability' mean for a product like Rexidin M FORTE?

A: Bioavailability describes the degree to which a drug is absorbed into the bloodstream. For this product, bioavailability is considered low because the main antimicrobial component is designed to remain bound to the oral tissues for local action. It is poorly absorbed through the digestive tract, and plasma levels are often undetectable.


Q: Is it necessary to inform my dentist that I am using Rexidin M FORTE?

A: Official patient guidance for the antimicrobial component indicates that regular dental visits may be appropriate during the course of treatment. This is to allow for the management of potential, expected side effects, such as reversible staining or the accumulation of tartar.


Q: What is the purpose of the mint flavoring or other excipients in the product?

A: In addition to the three active substances, the gel contains excipients (inactive ingredients). Regulatory-linked information shows these excipients often include materials like celluloses, which primarily function to assist with muco-adhesion. Muco-adhesion helps the product stick to the oral tissue to provide effective local contact time for the active ingredients.

Advertisements

How should Rexidin M FORTE be stored and disposed of?

Storage and Disposal of Rexidin M FORTE

Storage and disposal must strictly adhere to conditions established in official regulatory labeling for this combination gel containing Chlorhexidine and Metronidazole.

Official Storage Requirements

Condition Requirement
Temperature Store at room temperature, generally not exceeding 30 C (86 F).
Protection Must be protected from direct light, moisture, and excessive heat.
Handling Do not freeze the product. Keep the tube tightly closed in its original container.
Safety Keep the medicine out of the reach and sight of children at all times.

Disposal Instructions

Unused or expired Rexidin M FORTE must be disposed of according to local regulatory guidelines. Do not flush the product down the sink or toilet, as it is not on the government's official flush list. The preferred disposal method is utilizing official community drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Rexidin M FORTE found in:

A-Z Index: